NASDAQ:CGTX Cognition Therapeutics (CGTX) Stock Price, News & Analysis $0.45 0.00 (0.00%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Cognition Therapeutics Stock (NASDAQ:CGTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cognition Therapeutics alerts:Sign Up Key Stats Today's Range$0.42▼$0.4550-Day Range$0.40▼$0.7752-Week Range$0.34▼$2.95Volume212,443 shsAverage Volume478,427 shsMarket Capitalization$17.85 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingModerate Buy Company OverviewCognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Read More… I've got news for you… (Ad)Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the weekwatch this FREE briefing with me and expert trader Graham Lindman Cognition Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks76th Percentile Overall ScoreCGTX MarketRank™: Cognition Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 285th out of 1,013 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingCognition Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCognition Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Cognition Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cognition Therapeutics are expected to grow in the coming year, from ($0.96) to ($0.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cognition Therapeutics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cognition Therapeutics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCognition Therapeutics has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cognition Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.57% of the float of Cognition Therapeutics has been sold short.Short Interest Ratio / Days to CoverCognition Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cognition Therapeutics has recently decreased by 25.14%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCognition Therapeutics does not currently pay a dividend.Dividend GrowthCognition Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.57% of the float of Cognition Therapeutics has been sold short.Short Interest Ratio / Days to CoverCognition Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cognition Therapeutics has recently decreased by 25.14%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News SentimentN/A News SentimentCognition Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cognition Therapeutics this week, compared to 1 article on an average week.Search Interest6 people have searched for CGTX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Cognition Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cognition Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders20.75% of the stock of Cognition Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.35% of the stock of Cognition Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cognition Therapeutics' insider trading history. Receive CGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CGTX Stock News HeadlinesCognition Therapeutics, Inc. (NASDAQ:CGTX) Receives $8.00 Average Price Target from BrokeragesOctober 13, 2024 | americanbankingnews.comCognition Therapeutics Inc (CGTX) Q2 2024 Earnings Call Highlights: Promising Alzheimer's Trial ...October 9, 2024 | finance.yahoo.comMassive shakeup in defense contractingThere is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.October 17, 2024 | DTI (Ad)Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities ConferenceOctober 2, 2024 | markets.businessinsider.comCognition Therapeutics Will Participate in the Roth Healthcare Opportunities ConferenceOctober 2, 2024 | globenewswire.comCognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common DementiaOctober 1, 2024 | globenewswire.comCognition Therapeutics (NASDAQ:CGTX) Stock, Insider Trading ActivitySeptember 26, 2024 | benzinga.comCognition Therapeutics (NASDAQ:CGTX) Stock, Short Interest ReportSeptember 25, 2024 | benzinga.comSee More Headlines CGTX Stock Analysis - Frequently Asked Questions How have CGTX shares performed this year? Cognition Therapeutics' stock was trading at $1.85 on January 1st, 2024. Since then, CGTX stock has decreased by 75.9% and is now trading at $0.4456. View the best growth stocks for 2024 here. How were Cognition Therapeutics' earnings last quarter? Cognition Therapeutics, Inc. (NASDAQ:CGTX) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.04. When did Cognition Therapeutics IPO? Cognition Therapeutics (CGTX) raised $45 million in an initial public offering on Friday, October 8th 2021. The company issued 3,768,116 shares at $11.00-$13.00 per share. How do I buy shares of Cognition Therapeutics? Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cognition Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cognition Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Eli Lilly and Company (LLY), Meta Platforms (META), General Electric (GE), Arista Networks (ANET) and Celestica (CLS). Company Calendar Last Earnings8/08/2024Today10/17/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGTX CUSIPN/A CIK1455365 Webwww.cogrx.com Phone412-481-2210FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$14.00 Low Stock Price Target$1.00 Potential Upside/Downside+1,695.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-118.11% Return on Assets-84.49% Debt Debt-to-Equity RatioN/A Current Ratio3.07 Quick Ratio3.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.76 per share Price / Book0.59Miscellaneous Outstanding Shares40,058,000Free Float31,805,000Market Cap$17.85 million OptionableNot Optionable Beta1.36 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:CGTX) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.